Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Managing antithrombotic therapy in atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) presents clinical challenges.
• Optimal peri- and postprocedural antithrombotic strategies require careful consideration of bleeding and ischemic risks.

Purpose of the Study:

• To systematically review current evidence on optimal antithrombotic regimens for AF patients undergoing PCI.
• To provide guidance on selecting anticoagulants and antiplatelet agents in the peri- and postprocedural setting.

Main Methods:

• Systematic review of updated scientific literature.
• Analysis of evidence regarding non-vitamin K oral anticoagulants (NOACs), vitamin K antagonists (VKAs), aspirin, and clopidogrel.

Main Results:

• Standard dose NOACs are generally preferred post-PCI for AF patients, with reduced doses for those at high bleeding risk.
• Triple therapy (NOAC, clopidogrel, aspirin) is recommended early post-stenting; aspirin cessation timing depends on risk assessment.
• Limited evidence exists for managing anticoagulation during elective or urgent PCI, with different approaches suggested for VKAs versus NOACs.

Conclusions:

• Non-vitamin K oral anticoagulants are the preferred choice for most AF patients post-PCI, with dose adjustments for bleeding risk.
• Individualized risk assessment is crucial for managing antithrombotic therapy, particularly regarding aspirin cessation and procedural anticoagulation.
• Further research is needed to clarify optimal strategies for specific patient populations and procedural scenarios.